IMAAVY™
(nipocalimab-aahu)
Medical inquiries
This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
IMAAVY™ (nipocalimab-aahu)
Medical Information
IMAAVY – Pregnancy Safety Study
Last Updated: 05/06/2025
Summary
- A pregnancy safety study will be initiated to monitor pregnancy outcomes in women exposed to IMAAVY during pregnancy.1
- This study will analyze information on pregnancy, pregnancy outcomes, maternal complications, and fetal, neonatal, and infant outcomes (up to 1 year after birth) from patients with documented exposure to IMAAVY during pregnancy.
- Additional details will be shared once the protocol is available.
References
| 1 | Data on File. Correspondence from Janssen Research & Development, LLC. (Communication dated April 29, 2025). Janssen Research & Development, LLC; 2025. |